DE20119321U1 - Pharmaceutical preparation - Google Patents
Pharmaceutical preparationInfo
- Publication number
- DE20119321U1 DE20119321U1 DE20119321U DE20119321U DE20119321U1 DE 20119321 U1 DE20119321 U1 DE 20119321U1 DE 20119321 U DE20119321 U DE 20119321U DE 20119321 U DE20119321 U DE 20119321U DE 20119321 U1 DE20119321 U1 DE 20119321U1
- Authority
- DE
- Germany
- Prior art keywords
- ginsenosides
- pharmaceutical preparation
- aglycone
- microapplication
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 22
- 229930182494 ginsenoside Natural products 0.000 claims description 34
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 9
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 9
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 229940089161 ginsenoside Drugs 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 3
- 229940100243 oleanolic acid Drugs 0.000 claims description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims description 2
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- XEEFSHTUESCNEP-ICNXTIMXSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-6-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12, Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O XEEFSHTUESCNEP-ICNXTIMXSA-N 0.000 claims 1
- IWDYQBDCEDNTDP-AOSWIFJRSA-N Notoginsenoside R4 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@@H](O)[C@@H](O)CO3)O2)O1 IWDYQBDCEDNTDP-AOSWIFJRSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 14
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 6
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LLPWNQMSUYAGQI-QBQUQATFSA-N Ginsenoside R1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LLPWNQMSUYAGQI-QBQUQATFSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Description
MEW 112MEW112
Die Erfindung bezieht sich auf ein pharmazeutisches Präparat, enthaltend Inhaltsstoffe von Ginsengextrakten und dessen Verwendung.The invention relates to a pharmaceutical preparation containing ingredients of ginseng extracts and its use.
Die Ginsengpflanze ist als Heilpflanze durch viele homöopathische Anwendungen bekannt. Den Inhaltsstoffen des Ginsengextraktes werden sehr unterschiedliche Wirkungen zugesprochen. So sollen entsprechende flüssige und feste Zubereitungen die natürliche Widerstandsfähigkeit des Organismus stärken und dessen Erholung nach Belastbarkeit beschleunigen.The ginseng plant is known as a medicinal plant through many homeopathic applications. The ingredients of the ginseng extract are said to have very different effects. The corresponding liquid and solid preparations are said to strengthen the natural resistance of the organism and accelerate its recovery after stress.
In der festen Darreichungsform liegen die Extrakte meistens in Form von Kapseln vor, die oral verabreicht werden. Derartige oral verabreichten homöopotische Applikationen machen zunächst eine Leberpassage durch, bevor sie durch den Blutstrom im Organismus verteilt werden. Bei diesem Applikationsweg kann der Wirkstoff weitgehend zu wirksamen Folgeprodukten abgebaut werden, bevor er den beabsichtigten Wirkungsort (Zellen, Gewebe, Organ) erreicht. Die Folge davon ist, dass nicht selten eine höhere Dosis oder mehrfache Injektionen oderIn the solid dosage form, the extracts are usually in the form of capsules that are administered orally. Such orally administered homeopathic applications first pass through the liver before they are distributed throughout the body through the bloodstream. With this route of administration, the active ingredient can be largely broken down into effective secondary products before it reaches the intended site of action (cells, tissue, organ). The consequence of this is that a higher dose or multiple injections or
orale Verabreichungen pro Tag erforderlich sind, um eine therapeutisch wirksame Konzentration im Körper aufrechtzuerhalten.Oral administrations per day are required to maintain a therapeutically effective concentration in the body.
Aufgabe der Erfindung ist es daher, ein pharmazeutisches Präparat, enthaltend Inhaltsstoffe von Ginseng-Extrakten mit verbesserter Wirkstoffverfügbarkeit bei minimaler Belastung des restlichen Organismus bereitzustellen.The object of the invention is therefore to provide a pharmaceutical preparation containing ingredients of ginseng extracts with improved active ingredient availability with minimal stress on the rest of the organism.
Erfindungsgemäß wird die Aufgabe durch ein pharmazeutisches Präparat mit einem Gehalt an Ginsenosiden in Mikroapplikationshüllen gelöst.
Gemäß einer bevorzugten Ausführungsform des pharmazeutischen Präparates sind die Mikroapplikationshüllen durch Liposome oder Nanopartikel gebildet oder weist die Mikroapplikationshülle eine mehrschichtige Membran auf.According to the invention, the object is achieved by a pharmaceutical preparation containing ginsenosides in microapplication shells.
According to a preferred embodiment of the pharmaceutical preparation, the microapplication shells are formed by liposomes or nanoparticles or the microapplication shell has a multilayer membrane.
Eine weitere bevorzugte Ausführungsform der Erfindung sieht vor, dass die Ginsenoside solche der Gruppe Aglykon (20S)-Protopanaxadiol mit den Ginsenosiden Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, den Notoginsenosiden R4, Rs1 und Rs2 und den Malonylginsenosiden Rb1, Rc und Rd und/oder der Gruppe Aglykon (20S)-Protopanaxtriol mit den Ginsenosiden Re, Rf, Rg1 und dem Notoginsenosid R1 und/oder der Aglykon Oleanolsäure mit den Ginsenosiden Ro und Chikusetsusasaponin-V sind.A further preferred embodiment of the invention provides that the ginsenosides are those of the group aglycone (20S)-protopanaxadiol with the ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, the notoginsenosides R4, Rs1 and Rs2 and the malonylginsenosides Rb1, Rc and Rd and/or the group aglycone (20S)-protopanaxtriol with the ginsenosides Re, Rf, Rg1 and the notoginsenoside R1 and/or the aglycone oleanolic acid with the ginsenosides Ro and chikusetsusasaponin-V.
Als eine besonders bevorzugte Ausführungsform der Erfindung hat sich das pharmazeutische Präparat mit einem Gehalt an mindestens einem der Ginsenoside RI1 R4, RaI1 Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf1 Rg1, Rs1, Rs2, Ro oder Chikusetsusasaponin-V oder an mehreren der genannten Ginsenoside im Gemisch oder in Kombination mit über an der Mikroapplikationshülle gekoppelte Liganden verbundenen anderen Wirkstoffen erwiesen.A particularly preferred embodiment of the invention is the pharmaceutical preparation containing at least one of the ginsenosides RI 1 R4, RaI 1 Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf 1 Rg1, Rs1, Rs2, Ro or chikusetsusasaponin-V or several of the ginsenosides mentioned in a mixture or in combination with other active ingredients linked via ligands coupled to the microapplication shell.
Der besondere Vorzug der Erfindung besteht darin, dass erstmals das therapeutische Potential von Mikroapplikationshüllen für Ginsenoside mit der erfindungsgemäßen Lösung in Form eines „Drug Targeting" erschlossen wird. Die neue Applikationsform ermöglicht vielfältige neue Einsatzmöglichkeiten pharmazeutischer Präparate einschließlich von Arzneimitteln mit einem GehaltanThe particular advantage of the invention is that the therapeutic potential of microapplication shells for ginsenosides is exploited for the first time with the solution according to the invention in the form of "drug targeting". The new application form enables a wide range of new applications for pharmaceutical preparations, including drugs containing
Ginsenosiden und die unterschiedlichen pharmakologischen Wirkungen der Ginsenoside auf effektive Weise auszuschöpfen.Ginsenosides and the different pharmacological effects of ginsenosides in an effective manner.
Mit der Erfindung ist es möglich, das Freigabeverhalten des pharmazeutischen Präparates hinsichtlich der Ginsenoside am Zielort zu optimieren sowie deren Abgaberate zu kontrollieren und die Dauer der Wirksamkeit der Ginsenoside bei den Zielzellen zu steuern. Mittels des erfindungsgemäßen Applikationsweges können die Ginsenoside direkt in das Innere der Zielzelle gebracht werden. Die Ginsenoside sind dadurch vor dem Angriff von Körperflüssigkeiten und damit vor dem Zerfall bei Eingabe in den Organismus geschützt. Sie können am Zielort ihre volle Wirksamkeit entfalten. Durch die „Verpackung" in Mikroapplikationshüllen können die Ginsenoside enthaltenden pharmakologischen Zusammensetzungen erstmals auch intravenös verabreicht werden.The invention makes it possible to optimize the release behavior of the pharmaceutical preparation with regard to the ginsenosides at the target site, as well as to control their release rate and the duration of the effectiveness of the ginsenosides in the target cells. Using the application route according to the invention, the ginsenosides can be brought directly into the interior of the target cell. The ginsenosides are thus protected from attack by body fluids and thus from decomposition when introduced into the organism. They can develop their full effectiveness at the target site. By "packaging" them in micro-application shells, the pharmacological compositions containing ginsenosides can also be administered intravenously for the first time.
Überraschend wurde gefunden, dass einzelne in Mikroapplikationshüllen verpackten Ginsenosiden eine besondere therapeutische Wirkung haben und zur Verwendung als Arzneimittel geeignet sind.Surprisingly, it was found that individual ginsenosides packaged in microapplication shells have a special therapeutic effect and are suitable for use as medicinal products.
Hochreine Ginsenoside wurden als Einzelkomponenten in einer HPLC-Anlage isoliert, in Liposomen verpackt und für pharmakologische Studien eingesetzt.
In einer derartigen Studie wurde die Wirksamkeit des Ginsenosides Rg1, verpackt in einer Lipid-Formulierung, für die in der Literatur ein Lebertargeting beschrieben ist, an Ratten mit akuter Leberschädigung untersucht. Die Studie wurde mit einer Dosierung von 0,1 mg bis 50,0 mg reinem Ginsenosid Rg 1 pro ml Liposom durchgeführt.Highly pure ginsenosides were isolated as individual components in an HPLC system, packaged in liposomes and used for pharmacological studies.
In one such study, the efficacy of ginsenoside Rg1, packaged in a lipid formulation for which liver targeting is described in the literature, was investigated in rats with acute liver injury. The study was carried out with a dosage of 0.1 mg to 50.0 mg of pure ginsenoside Rg 1 per ml liposome.
Bereits nach 7 Tagen war ein Wirkungseintritt festzustellen. Im Ergebnis der Studie konnte unerwartet und überraschend festgestellt werden, dass durch das Ginsenosid Rg1 eine Gewebeerneuerung an der Leber der Ratte bewirkt wurde. Erstmals kann so ein pharmazeutisches Präparat bereitgestellt werden, deren Verwendung für die therapeutische Behandlung von Lebertumoren, Leberzirrhosen und anderen chronischen Lebererkrankungen geeignet ist.
Studien haben des weiteren ergeben, dass erfindungsgemäße pharmazeutische Präparate mit einem Gehalt an dem Ginsenosid Ro zur Therapie von Hepatitis geeignet sind.The effect was noticeable after just 7 days. The result of the study was unexpectedly and surprisingly found to be that the ginsenoside Rg1 caused tissue renewal in the rat liver. For the first time, a pharmaceutical preparation can be made available that is suitable for the therapeutic treatment of liver tumors, liver cirrhosis and other chronic liver diseases.
Studies have further shown that pharmaceutical preparations according to the invention containing the ginsenoside Ro are suitable for the treatment of hepatitis.
• · · · · · ·· · · · · ·
Erfindungsgemäße Präparate mit einem Gehalt an den Ginsenosiden Rb1 und Rg1 sind vorzugsweise zur Therapie von Aggressionen, solche mit einem Gehalt an dem Ginsenosid Rb zur Therapie bei Herzerkrankungen und Präparate mit einem Gehalt an den Ginsenosiden Rb1 und Rg3 zum Schutz von Nervenzellen geeignet.Preparations according to the invention containing the ginsenosides Rb1 and Rg1 are preferably suitable for the treatment of aggression, those containing the ginsenoside Rb for the treatment of heart diseases and preparations containing the ginsenosides Rb1 and Rg3 for the protection of nerve cells.
Die erfindungsgemäßen Verwendungen des neuen pharmazeutischen Präparates ergeben sich aus den Merkmalen der Ansprüche 7 bis 28.The uses of the new pharmaceutical preparation according to the invention result from the features of claims 7 to 28.
Zweckmäßig ist es, die für die Verpackung einzusetzende Lipidkomposition entsprechend ihrem organspezifischen Targeting, wie es sich aus dem bekannten Stand der Technik ergibt, auszuwählen und in Übereinstimmung mit der Targetingstrategie darin das Ginsenosid oder das Gemisch an Ginsenosiden mit der betreffenden organspezifischen Wirkung zu verpacken.It is expedient to select the lipid composition to be used for packaging according to its organ-specific targeting, as is apparent from the known state of the art, and to package the ginsenoside or the mixture of ginsenosides with the relevant organ-specific effect therein in accordance with the targeting strategy.
Die Verpackung der Ginsenoside kann auch nach den sich aus dem DE 198 52 928 C1 ergebenden technischen Lösungen erfolgen.The packaging of the ginsenosides can also be carried out according to the technical solutions resulting from DE 198 52 928 C1.
Des weiteren ist es möglich, die Ginsenoside oder deren Mischungen nach der bekannten und in der Literatur beschriebenen Kavitator-Technologie zu verpacken.Furthermore, it is possible to package the ginsenosides or their mixtures using the well-known cavitator technology described in the literature.
Insgesamt bieten die erfindungsgemäßen Lösungen völlig neue und kostengünstige Ansatzpunkte für das therapeutische Anwendungsfeld der einzelnen Ginsenoside und deren Kompositionen und die Erhöhung der therapeutischen Effizienz pharmazeutischer Präparate durch deren Konzentration am Wirkungsort.Overall, the solutions according to the invention offer completely new and cost-effective starting points for the therapeutic application field of the individual ginsenosides and their compositions and the increase in the therapeutic efficiency of pharmaceutical preparations by their concentration at the site of action.
So ist das erfindungsgemäße pharmazeutische Präparat zur therapeutischen Behandlung von Lebertumoren, Leberzirrhose oder anderen Lebererkrankungen, des weiteren zur therapeutischen Behandlung von Diabetes Mellitus und von HlV-infizierten Personen verwendbar.Thus, the pharmaceutical preparation according to the invention can be used for the therapeutic treatment of liver tumors, liver cirrhosis or other liver diseases, and also for the therapeutic treatment of diabetes mellitus and of HIV-infected persons.
Ferner ist das Präparat als Infektionsprophylaktikum und zur Therapie von Infektionen, wie der von Candida albicans, zur Stimulierung des Immunsystems,Furthermore, the preparation is used as an infection prophylactic and for the treatment of infections such as Candida albicans, to stimulate the immune system,
vorzugsweise bei Personen mit einem chronischen Pseudomonas aeruginosa sowie zur therapeutischen Behandlung von kurz- und längerfristiger Blutdrucksteigerung und zur Senkung des Cholesterinspiegels einsetzbar.Preferably used in people with chronic Pseudomonas aeruginosa as well as for the therapeutic treatment of short- and long-term increases in blood pressure and for lowering cholesterol levels.
Weitere Verwendungen kann das pharmazeutische Präparat zur therapeutischen Behandlung von Tumoren, zur Stärkung der Leistungs-, Gedächtnis- und Konzentrationsfähigkeit, zur therapeutischen Behandlung von Stresssituationen, zur Prevention und Therapie der Abhängigkeit von Morphinen, Kokain, Methamphetaminen und Alkohol, zur therapeutischen Behandlung erectiler Dysfunction, zur therapeutischen Behandlung bei Herzerkrankungen sowie zur therapeutischen Behandlung hormonaler Effekte finden.The pharmaceutical preparation can also be used for the therapeutic treatment of tumors, for strengthening performance, memory and concentration, for the therapeutic treatment of stress situations, for the prevention and treatment of addiction to morphine, cocaine, methamphetamine and alcohol, for the therapeutic treatment of erectile dysfunction, for the therapeutic treatment of heart diseases and for the therapeutic treatment of hormonal effects.
Es ist außerdem einsetzbar als Aphrodisiaca remedia.It can also be used as an aphrodisiac remedy.
Geeignet ist das erfindungsgemäße Präparat auch zur therapeutischen Behandlung von Kälte- und Wärmestauungen, von Depressionen und von Aggressionen.The preparation according to the invention is also suitable for the therapeutic treatment of cold and heat accumulation, depression and aggression.
Das pharmazeutische Präparat schützt Nervenzellen und bietet Schutz gegen Gamma-Stahlung.The pharmaceutical preparation protects nerve cells and provides protection against gamma radiation.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20119321U DE20119321U1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20119321U DE20119321U1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE20119321U1 true DE20119321U1 (en) | 2002-05-29 |
Family
ID=7964528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE20119321U Expired - Lifetime DE20119321U1 (en) | 2001-11-19 | 2001-11-19 | Pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE20119321U1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006026924A1 (en) * | 2004-09-08 | 2006-03-16 | Zelin Li | The use of ginsenoside in the treatment of aids |
| EP2036566A4 (en) * | 2006-06-09 | 2011-06-15 | Shanghai Innovative Res Ct Of Traditional Chinese Medicine | USE OF 20 (S) -PROTOPANOXADIOL IN THE MANUFACTURE OF ANTIDEPRESSANTS |
| US20130040903A1 (en) * | 2007-11-30 | 2013-02-14 | Zuoguang Zhang | Pharmaceutical compositions for treating depression and anxiety |
| WO2014178803A1 (en) * | 2013-04-29 | 2014-11-06 | Alkoçlar Erdal Can | A composition for use in the treatment of alcohol addiction |
| CN105998115A (en) * | 2016-05-16 | 2016-10-12 | 江西中医药大学 | Breviscapine-panax notoginseng saponins double-pharmaceutical nano-composite particle and preparation method and application thereof |
-
2001
- 2001-11-19 DE DE20119321U patent/DE20119321U1/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006026924A1 (en) * | 2004-09-08 | 2006-03-16 | Zelin Li | The use of ginsenoside in the treatment of aids |
| EP2036566A4 (en) * | 2006-06-09 | 2011-06-15 | Shanghai Innovative Res Ct Of Traditional Chinese Medicine | USE OF 20 (S) -PROTOPANOXADIOL IN THE MANUFACTURE OF ANTIDEPRESSANTS |
| US20130040903A1 (en) * | 2007-11-30 | 2013-02-14 | Zuoguang Zhang | Pharmaceutical compositions for treating depression and anxiety |
| WO2014178803A1 (en) * | 2013-04-29 | 2014-11-06 | Alkoçlar Erdal Can | A composition for use in the treatment of alcohol addiction |
| CN105998115A (en) * | 2016-05-16 | 2016-10-12 | 江西中医药大学 | Breviscapine-panax notoginseng saponins double-pharmaceutical nano-composite particle and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60117711T2 (en) | ANTINEOPLASTIC MEDICAMENT | |
| DE69923471T2 (en) | INJECTABLE PROPOFOL FORMULATIONS | |
| DE60220958T2 (en) | DEVELOPMENT OF A HUSTENSTILLEN AND ANTI-INFLAMMATORY FORMULATION FROM HERBS | |
| DE10158281A1 (en) | Pharmaceutical preparation comprises ginsenoside enclosed in micro-shell, e.g. liposome, providing targeted and controlled delivery, useful e.g. in treatment of liver tumors, diabetes mellitus or hypertension | |
| DE19838848A1 (en) | Composition containing pyrrolizidine alkaloid-free petasites | |
| DE69215999T2 (en) | Therapeutic agents for the treatment of drug resistance to cancer | |
| EP0869807B1 (en) | Use of a medicament and use of mixture of substances to produce a medicament | |
| DE69805096T2 (en) | USE OF GINKGO BILOBA EXTRACTS FOR PRODUCING A MEDICINAL PRODUCT | |
| DE20119321U1 (en) | Pharmaceutical preparation | |
| EP1150681A2 (en) | Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence | |
| EP0505519A1 (en) | Kava extract, method of preparing the extract, and its use. | |
| EP1399173A2 (en) | Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor | |
| DE19726871C1 (en) | Synergistic compositions for the selective control of tumor tissue | |
| DE3445183A1 (en) | PROGLUMID CONTAINING MEDICINES WITH ANALGETIC EFFECT | |
| WO2005076750A2 (en) | A novel synergistic herbal formulation for diabetes cure | |
| DE69424679T2 (en) | COMPOSITION FOR TREATING OR PREVENTING HERPES | |
| DE2325070A1 (en) | PHARMACEUTICAL PREPARATIONS FOR THE PROPHYLAXIS AND TREATMENT OF CAPILLARY VENUS DISEASES | |
| WO2001034169A1 (en) | Use of an extract from plantago lanceolata | |
| DE19530708C2 (en) | Pharmaceutical preparation with trypanocidal properties | |
| EP1871340B1 (en) | Anti-irritating cough mixture containing extracts from island moss and mallow as well as zinc derivatives | |
| DE3840946A1 (en) | USE OF ALUMINUM POTASSIUM SULFATE AND / OR 1 OR MORE OF ITS HYDRATES | |
| DE3511236C2 (en) | ||
| LU601121B1 (en) | The use of β-red myrcene in drugs for the prevention and improvement of acute liver damage | |
| DE10238161A1 (en) | Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule | |
| DE60206467T2 (en) | Detoxifying phytotherapeutic composition of two plant extracts and process for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 20020704 |
|
| R156 | Lapse of ip right after 3 years |
Effective date: 20050601 |